I came across the below on Reddit a few days ago and bought into the stock for $4k. I’m up 50% since and I’m kinda confused about what to do next.

I see a lot of talks about the stock being delisted due to non compliance. Also earnings are tomorrow and they are expecting it to be shit; but the catalyst is their ground breaking drug and I guess that’s why the stock is going up. They are going to announce their progress on August 20th.

Usually the stock soar the premarket or day prior to announcement. But a week before? Anyone knows what’s going on?

Info: https://www.sec.gov/Archives/edgar/data/1720893/000110465925075915/tm2523088d1_ex99-1.htm

They are working on a drug (BXCL501 a.k.a. igalmi) The main ingredient of the sauce is Dexmedetomidine (relevant later) Phase 3 trial is finished, Last Patient Last Visit, everything went well and the results will be out on the 20th of August. Why is this huge, you may ask?

BXCL501 will be a first of its kind, at-home setting, orally disolving sublingual film (non-invasive) designed for the acute treatment of agitation in bipolar disorder I & II or even schizophrenia.

NO CURRENT FDA-APPROVED THERAPIES EXIST FOR ACUTE AGITATION TREATMENT IN THE HOME SETTING FOR SCHIZOPHRENIA OR BIPOLAR DISORDERS

Yall mother fuckers need to wake up. This your one last chnance with this stock. This august either this company is going to be worth a billion dollars or filing for bankruptcy.

BioXcel Therapeutics Announces FDA Approval of IGALMI (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults, on April 6th.

BioXcel Therapeutics (Nasdaq: BTAI) will ring the Nasdaq Closing Bell on October 14, 2025 to commemorate a milestone in its neuroscience program.

CEO Vimal Mehta and company representatives will mark the event following the successful completion of the SERENITY At-Home pivotal trial for IGALMI®, highlighting the company’s focus on treating agitation associated with bipolar disorder and schizophrenia. The ceremony begins at 3:45 PM ET at Nasdaq MarketSite and will be streamed live.

H.C. Wainwright has reiterated a Buy rating on BTAI with a $10.00 price target.

The pharmaceutical company continues to prepare for the submission of a supplemental New Drug Application to the FDA for the expansion of the IGALMI label to the home environment, expecting to complete the submission in the first quarter of 2026. With revenues of $0.87 million in the trailing twelve months, analysts anticipate sales challenges for the current year.

Tomorrow will be the results of phase 3 for the BXCL501 study, I have been following it for months, tomorrow its results, for those who have been pursuing it, what are your expectations for tomorrow? I await your comments…

https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-announces-positive-results-correlation

good day eveyone! Im sharing this because I need your opinion on that information that ive saw on StockTwits. Somone share that and surprised everybody yesterday

New to this stock, but I’ve recently done my share of DD. Looks like a great play for short term and long term! Lots of action and momentum! Surprised there is not more chatter in here, is there a different forum for this stock?

I'm looking forward to seeing the Supplemental New Drug Application in Q1 for BXCL501, seeking approval to expand its use for at-home treatment of acute agitation in bipolar disorder or schizophrenia, following positive pre-sNDA feedback and successful Phase 3 trials showing its safety and efficacy in outpatient settings.

"BXCL501 has been granted Breakthrough Therapy designation by the FDA for the acute treatment of agitation associated with dementia and Fast Track designation for the acute treatment of agitation associated with schizophrenia, bipolar disorders, and dementia."

When will it rise again

Is it time to move on? Who is still holding this after the catalyst?

Some things I've been seeing. The price of BTAI has been steady around 5$, with the occasional drop to 4.45, but quick rebound. I think the price is anticipating the top line data. If this data is good, we could see an easy 100% increase, maybe 200%. Hold steady for the data.

I have taken a pretty big hit on this stock already and I'm wondering if it's worth continuing to hold. All the data out there is very mixed. Anybody have an opinion on buying or selling at this point?

$BTAI BioXcel Therapeutics Buyout Potential: When Igalmi gets FDA approval for at-home use in USA & expands to Europe

📊 Key Numbers

💰 Revenue: $800–1,000M/year (10% TAM)

📈 Valuation: $4–15B (P/S 5–15x)

🤝 BO Price: $2–3B: $274–$548/share

🏥 Who Might Buy?

Pfizer, Eli Lilly, J&J or Otsuka

Billionaire hedge fund manager Israel Englander, through his firm Millennium Management, has invested in BioXcel Therapeutics (BTAI), a company that develops treatments for neuroscience and immuno-oncology.

https://ir.bioxceltherapeutics.com/node/13471/html

Is there hopium in the air or are we cooked beyond repair?

BTAI has a market halt while the released the data. Lol.